SVV-001 is unique among members of the Picornaviradae family in that transgenes can be inserted into the SVV-001 genome and expressed specifically within the tumor.  Transgenes can code for proteins to provide additional safety over non-specific treatments.  Transgenes coding for immune-modulatory elements further enhance the anti-cancer immune response. Transgenes that code for proteins can eliminate negatively modulate elements within the tumor that suppress the anti-tumor response.  Versions of SVV-001 are also being constructed to encode tumor antigens.

ANti-cancer activity

Seneca Therapeutics currently has an open IND for a Clinical Trial titled “ A Phase 1 Trial of the Oncolytic Virus SVV-001 in Combination with Nivolumab in Patients with Poorly Differentiated Neuroendocrine Carcinomas and Well-Differentiated Neuroendocrine Tumors” We will be using an SVV-001 companion diagnostic (biomarker) to determine if a patient’s tumor is likely to be respond to SVV-001 in combination with checkpoint inhibitor therapy.

SVV variants are currently being developed to target many difficult-to-treat solid tumor cancer indications. Some of our armed viruses are in the pre-clinical development stage.

neutralizing antibody evasion

Our program aims to develop complimentary approaches to evade neutralizing antibodies that will enable successful multiple intravenous administrations of SVV-001.

LIBRARY TECHNOLOGY

• Capsid mutagenesis to identify mutants that evade nAb

• Capsid modifications to incorporate DARPINs

• Genome saturation mutagenesis (to improve virus stability and new insertion sites)

• 3D polymerase mutagenesis to reduce recombination